Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector

Molecular Therapy

Volumn 17, Issue 11, 2009, Pages 1857-1867

  Manfredsson, Fredric P ^a   Burger, Corinna ^b   Rising, Aaron C ^a   Zuobi Hasona, Kheir ^a   Sullivan, Layla F ^a   Lewin, Alfred S ^a   Huang, Julia ^a   Piercefield, Emily ^a   Muzyczka, Nicholas ^a   Mandel, Ronald J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ETOPOSIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; LOW DRUG DOSE; MALE; NONHUMAN; PARKINSON DISEASE; RAT; REGULATORY MECHANISM; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DENSITOMETRY; DEPENDOVIRUS; DOXYCYCLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; MALE; RATS; RATS, SPRAGUE-DAWLEY; TETRACYCLINE;

ADENO-ASSOCIATED VIRUS; RODENTIA;

EID: 70449122321     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.196     Document Type: Article

References (50)

1. Fearnley, JM and Lees, AJ (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301.
2. Peterson, AL and Nutt, JG (2008). Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5: 270-280.
3. Bespalov, MM and Saarma, M (2007). GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28: 68-74.
4. Pascual, A, Hidalgo-Figueroa, M, Piruat, JI, Pintado, CO, Gómez-Díaz, R and López-Barneo, J (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11: 755-761.
5. Ibanez, CF (2008). Catecholaminergic neuron survival: Getting hooked on GDNF. Nat Neurosci 11: 735-736.
6. Walker, DG, Beach, TG, Xu, R, Lile, J, Beck, KD, McGeer, EG et al. (1998). Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease. Brain Res 792: 207-217.
7. Bartus, RT, Herzog, CD, Bishop, K, Ostrove, JM, Tuszynski, M, Kordower, JH et al. (2007). Issues regarding gene therapy products for Parkinson's disease: The development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord 13 (suppl. 3): S469-S477.
8. Mandel, RJ, Manfredsson, FP, Foust, KD, Rising, A, Reimsnider, S, Nash, K et al. (2006). Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 13 463-483.
9. Björklund, A, Kirik, D, Rosenblad, C, Georgievska, B, Lundberg, C and Mandel, RJ (2000). Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886: 82-98.
10. Kordower, JH, Palfi, S, Chen, EY, Ma, SY, Sendera, T, Cochran, EJ et al. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424.
11. Kordower, JH and Olanow, CW (2008). Regulatable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself? Exp Neurol 209: 34-40.
12. Cress, DE (2008). The need for regulatable vectors for gene therapy for Parkinson's disease. Exp Neurol 209: 30-33.
13. Gossen, M and Bujard, H (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551.
14. Georgievska, B, Jakobsson, J, Persson, E, Ericson, C, Kirik, D and Lundberg, C (2004). Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum Gene Ther 15: 934-944.
15. Chtarto, A, Bender, HU, Hanemann, CO, Kemp, T, Lehtonen, E, Levivier, M et al. (2003). Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther 10: 84-94.
16. Szulc, J and Aebischer, P (2008). Conditional gene expression and knockdown using lentivirus vectors encoding shRNA. Methods Mol Biol 434: 291-309.
17. Georgievska, B, Kirik, D and Björklund, A (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177: 461-474.
18. Rosenblad, C, Georgievska, B and Kirik, D (2003). Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17: 260-270.
19. Georgievska, B, Kirik, D and Björklund, A (2004). Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces timeand dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24: 6437-6445.
20. Sajadi, A, Bauer, M, Thöny, B and Aebischer, P (2005). Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J Neurochem 93: 1482-1486.
21. Manfredsson, FP, Tumer, N, Erdos, B, Landa, T, Broxson, CS, Sullivan, LF et al. (2009). Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 17: 980-991.
22. Hovland, DN, Boyd, RB, Butt, MT, Engelhardt, JA, Moxness, MS, Ma, MH et al. (2007). Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 35: 1013-1029.
23. Cochran, WG and Cox GM (1957). Experimental Design, 5th edn, New York: Wiley.
24. Marks, WJ, Ostrem, JL, Verhagen, L, Starr, PA, Larson, PS, Bakay, RA et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol 7: 400-408.
25. Szulc, J, Wiznerowicz, M, Sauvain, MO, Trono, D and Aebischer, P (2006). A versatile tool for conditional gene expression and knockdown. Nat Methods 3: 109-116.
26. Fitzsimons, HL, Bland, RJ and During, MJ (2002). Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 28: 227-236.
27. Goverdhana, S, Puntel, M, Xiong, W, Zirger, JM, Barcia, C, Curtin, JF et al. (2005). Regulatable gene expression systems for gene therapy applications: Progress and future challenges. Mol Ther 12: 189-211.
28. Ye, X, Rivera, VM, Zoltick, P, Cerasoli, F, Schnell, MA, Gao, G et al (1999). Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283: 88-91.
29. Chang, Q, Virag, T, Rampalli, S, Vanin, EF and Bohn, MC (2008). Molecular, cellular, and behavioral characterization of a tetracycline (Tet)-regulated rAAV vector for human aromatic amino acid decarboxylase (hAADC) in a rat model of Parkinson's disease (PD). Mol Ther 16 S264.
30. Baron, U, Gossen, M and Bujard, H (1997). Tetracycline-controlled transcription in eukaryotes: Novel transactivators with graded transactivation potential. Nucleic Acids Res 25: 2723-2729.
31. Lowenstein, PR (2002). Immunology of viral-vector-mediated gene transfer into the brain: An evolutionary and developmental perspective. Trends Immunol 23: 23-30.
32. Xiong, W, Candolfi, M, Kroeger, KM, Puntel, M, Mondkar, S, Larocque, D et al. (2008). Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther 16: 343-351.
33. Gill, G and Ptashne, M (1988). Negative effect of the transcriptional activator GAL4. Nature 334: 721-724.
34. Yueh, YG, Yaworsky, PJ and Kappen, C (2000). Herpes simplex virus transcriptional activator VP16 is detrimental to preimplantation development in mice. Mol Reprod Dev 55: 37-46.
35. Shockett, PE and Schatz, DG (1996). Diverse strategies for tetracycline-regulated inducible gene expression. Proc Natl Acad Sci USA 93: 5173-5176.
36. Cunha, BA, Sibley, CM and Ristuccia, AM (1982). Doxycycline. Ther Drug Monit 4: 115-135.
37. Stieger, K, Belbellaa, B, Le Guiner, C, Moullier, P and Rolling, F (2009). In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 61: 527-541.
38. Berman, B, Perez, OA and Zell, D (2007). Update on rosacea and anti-inflammatorydose doxycycline. Drugs Today 43: 27-34.
39. Tatarewicz, SM, Wei, X, Gupta, S, Masterman, D, Swanson, SJ and Moxness, MS (2007). Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 27: 620-627.
40. Peden, CS, Manfredsson, FP, Reimsnider, SK, Poirier, AE, Burger, C, Muzyczka, N et al. (2009). Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Mol Ther 17: 524-537.
41. Burger, C, Gorbatyuk, OS, Velardo, MJ, Peden, CS, Williams, P, Zolotukhin, S et al. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317.
42. Reimsnider, S, Manfredsson, FP, Muzyczka, N and Mandel, RJ (2007). Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15: 1504-1511.
43. Burger, C, Nguyen, FN, Deng, J and Mandel, RJ (2005). Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Mol Ther 11: 327-331.
44. Manfredsson, FP, Burger, C, Sullivan, LF, Muzyczka, N, Lewin, AS and Mandel, RJ (2007). rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp Neurol 207: 289-301.
45. Liu, Y, Okada, T, Shimazaki, K, Sheykholeslami, K, Nomoto, T, Muramatsu, S et al. (2008). Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea. Mol Ther 16: 474-480.
46. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 158-167.
47. Peden, CS, Burger, C, Muzyczka, N and Mandel, RJ (2004). Circulating anti-wildtype adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78: 6344-6359.
48. Tümer, N, Scarpace, PJ, Dogan, MD, Broxson, CS, Matheny, M, Yurek, DM et al. (2006). Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity. Neurobiol Aging 27: 459-470.
49. Kirk, RE (1968). Experimental Design: Procedures for the Behavioral Sciences. Belmont, CA: Brooks/Cole.
50. Ruz, N, Zabala, M, Kramer, MG, Campanero, MA, Dios-Viéitez, MC and Blanco-Príeto, MJ (2004). Rapid and simple determination of doxycycline in serum by highperformance liquid chromatography. Application to particulate drug delivery systems. J Chromatogr A 1031: 295-301.